Plasma Biomarker for Alzheimer’s Disease: Are We Ready Now for Clinical Practice and Drug Trials? A. Nakamura Editorial 12 June 2018 Pages: 158 - 159
Turning Point towards Blood Biomarker-Guided Targeted Therapy for Precision Medicine in Alzheimer’s Disease Harald HampelA. VergalloAlzheimer Precision Medicine Initiative (APMI) Editorial 13 June 2018 Pages: 160 - 164
WHO Guidelines on Community-Level Interventions to Manage Declines in Intrinsic Capacity: The Road to Prevention Cognitive Decline in Older Age? B. VellasD. ScraseL. T. Middleton Editorial 13 June 2018 Pages: 165 - 167
Fatty acids and Alzheimer’s Disease: Evidence on Cognition and Cortical β-amyloid from Secondary Analyses of the Multidomain Alzheimer Preventive Trial Claudie HooperB. VellasMAPT/DSA study group Commentary 20 February 2018 Pages: 168 - 170
What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force P. S. AisenE. SiemersEU/US/CTAD Task Force members CTAD Task Force Paper 29 May 2018 Pages: 171 - 174
Effects of a Six-Month Multi-Ingredient Nutrition Supplement Intervention of Omega-3 Polyunsaturated Fatty Acids, vitamin D, Resveratrol, and Whey Protein on Cognitive Function in Older Adults: A Randomised, Double-Blind, Controlled Trial Catherine MoranA. Scotto di PalumboB. Egan Brief Report 20 February 2018 Pages: 175 - 183
Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3 Hong Liu-SeifertE. SiemersP. Aisen Original Research 29 May 2018 Pages: 184 - 187
Detection of Rater Errors on Cognitive Instruments in a Clinical Trial Setting Donald J. ConnorC. W. JenkinsP. Perera Original Research 22 May 2018 Pages: 188 - 196
Auraptene in the Peels of Citrus Kawachiensis (Kawachibankan) Contributes to the Preservation of Cognitive Function: A Randomized, Placebo-Controlled, Double-Blind Study in Healthy Volunteers Michiya IgaseY. OkadaY. Ohyagi Original Research 19 December 2017 Pages: 197 - 201
Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial L. K. JoachimL. FrölichOliver Peters Original Research Open access 13 February 2018 Pages: 202 - 206
An Action Plan to Face the Challenge of Dementia: INTERNATIONAL STATEMENT ON DEMENTIA from IAP for Health H. ChertkowResearch Executive Committee of the Canadian Consortium on Neurodegeneration in AgingInternational IAP committee on Dementia Position Paper Open access 20 June 2018 Pages: 207 - 212